ELMTY yields 2.11% · JNJ yields 2.13%● Live data
📍 JNJ pulled ahead of the other in Year 6
Combined, ELMTY + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of ELMTY + JNJ for your $10,000?
Elementis plc operates as a specialty chemical company in the United Kingdom, North America, rest of Europe, and internationally. It operates through four segments: Personal Care, Coatings, Talc, and Chromium. The Personal Care segment produces and sells rheological modifiers and compounded products for antiperspirants/deodorants, bath and soap, color cosmetics, and hair and skin care products. The Coatings segment produces and sells rheological modifiers and additives for industrial finishes, architectural coatings, construction, adhesives and sealants, inks, colorant dispersions, and specialty applications; and bentonite and hectorite clays, as well as polymer-based additives used in drilling, simulation, and cementing applications. The Talc segment produces and supplies talc for use in plastics, paints and coatings, food and pharmaceuticals, ceramics, polyester putties, paper, and pulp sectors. The Chromium segment produces chromium chemicals, such as chromic oxide, chromic acid, chrome sulfate, sodium dichromate, and sodium sulfate for use in pigments, cosmetics, refractories, chrome metal production, metal and plastic finishing, wood treatment, leather tanning, trivalent metal finishing, coatings, and metal passivation, as well as for making detergents, glasses, papers, and starches. It also offers personal care products, waxes, additives and resins, organoclays, colourants, and other specialty additives. Elementis plc was founded in 1844 and is headquartered in London, the United Kingdom.
Full ELMTY Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.